Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2006-03-14
2006-03-14
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S001110, C424S001490, C424S001650, C424S001690, C424S009100
Reexamination Certificate
active
07011816
ABSTRACT:
A method and compositions are described for labeling a targeting agent with Ga-68, in which eluate from an acid-eluted Ge-68/Ga-68 generator is combined with a macrocycle-containing targetable agent. The labeling method and compositions disclosed ensure that a simple elution of gallium-68, taken directly from a generator, can be used without further manipulation to quantitatively label a macrocycle-containing targetable agent. The Ga-68 labeled targeting agent so produced is useful with specific targeting agents, and is most especially useful in a pretargeting method for positron emission tomographic detection.
REFERENCES:
patent: 5079346 (1992-01-01), Kung
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5364613 (1994-11-01), Sieving et al.
patent: 5639439 (1997-06-01), Lee et al.
patent: 6071490 (2000-06-01), Griffiths et al.
patent: 2003/0124057 (2003-07-01), Griffiths et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2004/0043030 (2004-03-01), Griffiths et al.
patent: WO 94/04485 (1994-03-01), None
patent: WO 98/04293 (1998-02-01), None
patent: WO 99/56792 (1999-11-01), None
Henze et al., “PET Imaging of Somatostatin Receptors Using [66GA]DOTA-D-PHE1Tyr3Octreotide: First Results in Patients with Meningiomas,”Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine(Jul. 2001), vol. 42, No. 7, pp. 1053-1056, XP002245466, ISSN: 0161-5505.
Heppeler et al., “Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides,”Current Medicinal Chemistry(2000), vol. 7, pp. 971-994, Bentham Science Publishers, XP000982225, ISSN: 0929-8673.
Shizuko Ambe, “68Ge-68Ga Generator with Alpha-ferric Oxide Support,”Appl. Radiat. Isot.; Int. J. Radiat. Appl. Instrum. Part A., 1988, pp. 49-51, vol. 39, No. 1, ®Pergamon Press Great Britain.
David A. Goodwin et al., “Rapid Synthesis and Quality Control of68Ga-labeled Chelates for Clinical Use,”Nucl. Med. Biol., 1994, pp. 897-899, vol. 21, No. 6, ®Pergamon Press Great Britain.
Mark A. Green et al., “Potential Gallium-68 Tracers for Imaging the Heart with PET: Evaluation of Four Gallium Complexes with Functionalized TripodalTris(Salicylaldimine) Ligands,”Journal of Nuclear Medicine, 1993, pp., 228-233, vol. 34., No. 2.
Donald J. Hnatowich, A Method for the Preparation and Quality Control of68Ga Radiopharmaceuticals,Journal of Nuclear Medicine, 1975, pp. 764-768, vol. 16, No. 8.
Gabor Klivenyi et al., “Gallium-68 Chelate Imaging of Human Colon Carcinoma Xenografts Pretargeted with Bispecific Anti-CD44v6/Anti-Calluim Chelate Antibodies,”The Journal of Nuclear Medicine, 1998, pp. 1769-1776, vol. 39, No. 10.
S. Kulprathipanja et al., “A Method for Determining the pH Stability Range of Gallium Radiopharmaceuticals,”The International Journal of Applied Radiation and Isotopes, 1977, pp. 229-233, vol. 28; Pergamon Press.
H.F. Kung et al., A New Myocardial Imaging Agent: Synthesis, Characterization, and Biodistribution of Gallium-68-BAT TECH,The Journal of Nuclear Medicine, 1990, pp. 1635-1640, vol. 31, No. 10.
Jaetae Lee et al., “In Vitro and In Vivo Evaluation of Structure-Stability Relationship of111In- and67Ga-Labeled Antibody via 1B4M or C-NOTA Chelates,”Nuclear Medicine and Biology, 1997, pp. 225-230, vol. 24, Elsevier Science.
R.E. Lewis et al., Germanium-68/Gallium-68 Generator for the One Step Elution of Ionic Gallium-68,Journal of Labelled Compounds&Radiopharmaceuticals, 1981, 164, vol. XVIII, Nos. 1-2.
C. Loc'h et al., “A New Generator for Ionic Gallium-68,”Nuclear Medicine, 1980, pp. 171-173, vol. 21, No. 2.
Karen D. Mcelvany et al., “Comparison of68Ge/68Ga Generator Systems for Radiopharmaceutical Production,”The International Journal of Applied Radiation and Isotopes, 1984, pp. 521-524, vol. 35, No. 6.
R.D. Neirinckx et al., “Potential Column Chromatography for Ionic Ga-68. II: Organic Ion Exhangers as Chromatographic Supports,”Journal of Nuclear Medicine, 1980, pp. 81-83, vol. 21, No. 1.
Jochen Schuhmacher et al., “Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography1,”Cancer Research, 1995, pp. 115-123, vol. 55, No. 1.
Yizhen Sun et al., “Indium (III) and Gallium (III) complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior,”Journal of Medical Chemistry, 1996, pp. 458-470, vol. 39, No. 2.
Chuanchu Wu et al., “Biodistribution and Catabolism of Ga-67-Labeled Anti-Tac dsFv Fragment,”Bioconjugate Chem., 1997, pp. 365-369, vol. 8, No. 3.
Brenda W. Tsang, et al., “A Gallium-68 Radiopharmaceutical That is Retained in Myocardium:68Ga[(4,6-MeO2sal)2BAPEN]+,”The Journal of Nuclear Medicine, 1993, pp. 1127-1131, vol. 34, No. 7.
Table of Contents,Journal of Nuclear Medicine, vol. 2, No. 1, Jan. 1961, Eighth Annual Meeting, Pennsylvania.
M.A. Gracheva, et al., The Reaction Mechanism of the Technetium 99-m Complex Formation with the Ligands used for the Preparation of Radiopharmaceutical Medicines,Journal of Labelled Compounds&Radiopharmaceuticals, 1982, pp. 1535-1536, vol. XIX, Nos. 11-12.
Hsu, et al., “Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators”, The Journal of Immunology, pp. 5993-5998 (2002).
Griffiths Gary L.
McBride William J.
Heller Ehrman LLP
Immunomedics Inc.
Jones Dameron L.
LandOfFree
Labeling targeting agents with gallium-68 and gallium-67 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Labeling targeting agents with gallium-68 and gallium-67, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Labeling targeting agents with gallium-68 and gallium-67 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3591122